DiogenX
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
DiogenX has raised €32M across 2 funding rounds from 6 investors, most recently a Series A round in May 2023. Based in Marseille, France; founded 2019; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€32M
€32,000,000
Funding rounds
2
Investors
6
distinct backers
Active since
2020-06
latest 2023-05
Funding by year
EUR raised per yearDiogenX — funding by year — interactive chart.
Data table
| DiogenX — funding by year | |
|---|---|
| 2020 | €4.5M |
| 2023 | €28M |
Signals
High confidenceRaise-next likelihood9
base rate 44% for Series A
- ▼ Past typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 7y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-05-10 | Series A | €28M | AdBio partners,Boehringer Ingelheim Venture Fund,Eli lilly and company,JDRF T1D Fund,Omnes Capital,Roche Venture Fund | View deal → |
| 2020-06-16 | Seed | €4.5M | — | View deal → |
Investors
6Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData